Fig. 1 · Structure
Documents & Downloads
Lunacalcipol
Vitamin D Receptor Agonist
Lunacalcipol is a vitamin D receptor agonist that acts through the modulation of vitamin D signaling pathways. It demonstrates dual functionality in chronic kidney disease (CKD) by enhancing the activity of the vitamin D receptor (VDR) and inhibiting the cytochrome P450 enzyme 24-hydroxylase. By binding to VDR, Lunacalcipol influences various aspects of its transcriptional activity, including ligand affinity and coactivator recruitment. This compound is particularly relevant for research focused on CKD and secondary hyperparathyroidism (sHPT).
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Agonist |
| CAS Number | 250384-82-8 |
| Applications | Vitamin D Receptor Agonist |
| Formula | C28H42O4S |
| Molecular Weight | 474.70 |
| Synonyms | CTA-018 |
| SMILES | C[C@@]12[C@](CC=C2[C@H](C)C/C=C/S(C(C)(C)C)(=O)=O)([H])/C(CCC1)=C/C=C3C([C@H](C[C@@H](C\3)O)O)=C |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.